Literature DB >> 15155195

Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread.

Natalia Cheshenko1, Marla J Keller, Veronica MasCasullo, Gary A Jarvis, Hui Cheng, Minnie John, Jin-Hua Li, Kathleen Hogarty, Robert A Anderson, Donald P Waller, Lourens J D Zaneveld, Albert T Profy, Mary E Klotman, Betsy C Herold.   

Abstract

Topical microbicides designed to prevent acquisition of sexually transmitted infections are urgently needed. Nonoxynol-9, the only commercially available spermicide, damages epithelium and may enhance human immunodeficiency virus transmission. The observation that herpes simplex virus (HSV) and human immunodeficiency virus bind heparan sulfate provided the rationale for the development of sulfated or sulfonated polymers as topical agents. Although several of the polymers have advanced to clinical trials, the spectrum and mechanism of anti-HSV activity and the effects on soluble mediators of inflammation have not been evaluated. The present studies address these gaps. The results indicate that PRO 2000, polystyrene sulfonate, cellulose sulfate, and polymethylenehydroquinone sulfonate inhibit HSV infection 10,000-fold and are active against clinical isolates, including an acyclovir-resistant variant. The compounds formed stable complexes with glycoprotein B and inhibit viral binding, entry, and cell-to-cell spread. The effects may be long lasting due to the high affinity and stability of the sulfated compound-virus complex, as evidenced by surface plasmon resonance studies. The candidate microbicides retained their antiviral activities in the presence of cervical secretions and over a broad pH range. There was little reduction in cell viability following repeated exposure of human endocervical cells to these compounds, although a reduction in secretory leukocyte protease inhibitor levels was observed. These studies support further development and rigorous evaluation of these candidate microbicides.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15155195      PMCID: PMC415621          DOI: 10.1128/AAC.48.6.2025-2036.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

1.  The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model.

Authors:  N Bourne; D I Bernstein; J Ireland; A J Sonderfan; A T Profy; L R Stanberry
Journal:  J Infect Dis       Date:  1999-07       Impact factor: 5.226

2.  Topical microbicides for disease prevention: status and challenges.

Authors:  Polly F Harrison; Zeda Rosenberg; Jana Bowcut
Journal:  Clin Infect Dis       Date:  2003-05-08       Impact factor: 9.079

Review 3.  Development of topical microbicides for prevention of human immunodeficiency virus and herpes simplex virus.

Authors:  M J Keller; M E Klotman; B C Herold
Journal:  Am J Reprod Immunol       Date:  2003-05       Impact factor: 3.886

Review 4.  Considerations and development of topical microbicides to inhibit the sexual transmission of HIV.

Authors:  Jim A Turpin
Journal:  Expert Opin Investig Drugs       Date:  2002-08       Impact factor: 6.206

Review 5.  Herpesvirus entry: an update.

Authors:  Patricia G Spear; Richard Longnecker
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

6.  Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial.

Authors:  Lut Van Damme; Gita Ramjee; Michel Alary; Bea Vuylsteke; Verapol Chandeying; Helen Rees; Pachara Sirivongrangson; Léonard Mukenge-Tshibaka; Virginie Ettiègne-Traoré; Charn Uaheowitchai; Salim S Abdool Karim; Benoît Mâsse; Jos Perriëns; Marie Laga
Journal:  Lancet       Date:  2002-09-28       Impact factor: 79.321

7.  Mandelic acid condensation polymer: novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry.

Authors:  B C Herold; I Scordi-Bello; N Cheshenko; D Marcellino; M Dzuzelewski; F Francois; R Morin; V Mas Casullo; R A Anderson; C Chany; D P Waller; L J D Zaneveld; M E Klotman
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

8.  Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men.

Authors:  Stephen R Tabet; Marianne M Callahan; Christine K Mauck; Fang Gai; Anne S Coletti; Albert T Profy; Thomas R Moench; Lydia E Soto-Torres; Alfred N Poindexter III; Ron G Frezieres; Terri L Walsh; Clifton W Kelly; Barbra A Richardson; Lut Van Damme; Constance L Celum
Journal:  J Acquir Immune Defic Syndr       Date:  2003-08-01       Impact factor: 3.731

9.  Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women.

Authors:  Kenneth H Mayer; Salim Abdool Karim; Clifton Kelly; Lisa Maslankowski; Helen Rees; Albert T Profy; Jennifer Day; Julie Welch; Zeda Rosenberg
Journal:  AIDS       Date:  2003-02-14       Impact factor: 4.177

10.  NP-1, a rabbit alpha-defensin, prevents the entry and intercellular spread of herpes simplex virus type 2.

Authors:  Sara Sinha; Natalia Cheshenko; Robert I Lehrer; Betsy C Herold
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

View more
  45 in total

1.  Digallate dimers of (-)-epigallocatechin gallate inactivate herpes simplex virus.

Authors:  Charles E Isaacs; Weimin Xu; George Merz; Sharon Hillier; Lisa Rohan; Guang Y Wen
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

Review 2.  Proteoglycans in host-pathogen interactions: molecular mechanisms and therapeutic implications.

Authors:  Allison H Bartlett; Pyong Woo Park
Journal:  Expert Rev Mol Med       Date:  2010-02-01       Impact factor: 5.600

3.  Dynasore disrupts trafficking of herpes simplex virus proteins.

Authors:  Mascha B Mues; Natalia Cheshenko; Duncan W Wilson; Leslie Gunther-Cummins; Betsy C Herold
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

4.  Critical design features of phenyl carboxylate-containing polymer microbicides.

Authors:  Robert F Rando; Sakae Obara; Mark C Osterling; Marie Mankowski; Shendra R Miller; Mary L Ferguson; Fred C Krebs; Brian Wigdahl; Mohamed Labib; Hiroyasu Kokubo
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 5.  Non-specific microbicide product development: then and now.

Authors:  Joseph W Romano; Melissa Robbiani; Gustavo F Doncel; Thomas Moench
Journal:  Curr HIV Res       Date:  2012-01-01       Impact factor: 1.581

6.  Griffithsin protects mice from genital herpes by preventing cell-to-cell spread.

Authors:  Briana Nixon; Martha Stefanidou; Pedro M M Mesquita; Esra Fakioglu; Theodore Segarra; Lisa Rohan; William Halford; Kenneth E Palmer; Betsy C Herold
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

7.  PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial.

Authors:  Sheena McCormack; Gita Ramjee; Anatoli Kamali; Helen Rees; Angela M Crook; Mitzy Gafos; Ute Jentsch; Robert Pool; Maureen Chisembele; Saidi Kapiga; Richard Mutemwa; Andrew Vallely; Thesla Palanee; Yuki Sookrajh; Charles J Lacey; Janet Darbyshire; Heiner Grosskurth; Albert Profy; Andrew Nunn; Richard Hayes; Jonathan Weber
Journal:  Lancet       Date:  2010-09-17       Impact factor: 79.321

8.  HSV usurps eukaryotic initiation factor 3 subunit M for viral protein translation: novel prevention target.

Authors:  Natalia Cheshenko; Janie B Trepanier; Theodore J Segarra; A Oveta Fuller; Betsy C Herold
Journal:  PLoS One       Date:  2010-07-27       Impact factor: 3.240

9.  Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections.

Authors:  Rebecca Pellett Madan; Pedro M M Mesquita; Natalia Cheshenko; Bingwen Jing; Vikas Shende; Esmeralda Guzman; Taylor Heald; Marla J Keller; Steven L Regen; Robin J Shattock; Betsy C Herold
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

10.  Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials.

Authors:  Marla J Keller; Pedro M M Mesquita; N Merna Torres; Sylvia Cho; Gail Shust; Rebecca P Madan; Hillel W Cohen; Julie Petrie; Tara Ford; Lydia Soto-Torres; Albert T Profy; Betsy C Herold
Journal:  PLoS One       Date:  2010-01-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.